ATAZANAVIR SULFATE
Post-LOEANDAORALCAPSULE
Approved
Aug 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ATAZANAVIR SULFATE by Cipla is hiv-1 antiretroviral drug [see ] . First approved in 2018.
Drug data last refreshed 20h ago
Mechanism of Action
HIV-1 antiretroviral drug [see ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Cipla
India - Mumbai
Worked on ATAZANAVIR SULFATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.